X4 Pharmaceuticals (XFOR) Q3 2026 earnings review
The FDA accepted X4's smaller trial, and its sales grew
X4 Pharmaceuticals won a cheaper path to its trial result, but it still cannot fund a launch. The US regulator accepted a smaller study of 126 participants, and executive chairman Adam Craig said enrollment finishes by the end of December. Sales of the approved pill reached $2.8 million, and the quarterly loss narrowed to $20.2 million.
| Sales of its approved pill in the US | $2.8 million +77% from a year ago |
|---|---|
| Net loss | $20.2 million $29.8 million a year ago |
| Cash, equivalents and marketable securities | $187.7 million $253.0 million at the end of 2025 |
| Cash runway outlook | Into early 2029 end of 2028 a year ago |
⚖️ Verdict: 🟢 Bullish
The case got better, because the regulator accepted a smaller study and a new lender moved debt repayment years past the trial result. Craig says enrollment closes this quarter, which keeps the timetable intact. One caution: X4 tells investors its money covers only the next twelve months, and the extra credit it arranged may pay for acquisitions, not for selling a drug.
The question now is whether a study this size supports the label X4 needs. The regulator confirmed the power of the main measures, but said nothing as firm about the secondary ones or the safety database. Topline results in early 2028 settle it.
🐂 Bull Case
FDA Accepted a Smaller 4WARD Trial
X4 Pharmaceuticals tests mavorixafor, a once-daily pill, in people with primary chronic neutropenia, a rare blood disorder that leaves the body short of the white cells that fight infection. The 4WARD study decides whether that pill reaches those patients.
In August the US Food and Drug Administration replied to a Type C meeting request and said that cutting the study from 176 participants to 126 "maintains adequate overall power for the co-primary endpoints of the reduction in annualized infection rate and positive absolute neutrophil count response".
- Participants needed: 126, against a target of 176 a year ago
- Power on the neutrophil count measure: 93%
- Power on the yearly infection rate: 89%
- Topline results: expected in the first quarter of 2028
Fewer volunteers means X4 fills the last places sooner and pays less for them. Craig said the team remains "on track to complete our target enrollment of 126 participants by the end of this year", so the results still arrive in early 2028.
What to watch: whether X4 confirms a full study before January. The agency has not said the smaller trial keeps enough power for the secondary measures, and X4 plans to send it more information; a supportive reply widens the label the company can request.
New Lender Pushes Repayment Past the Data
X4 owed its previous lender $75 million, and the whole sum fell due in July 2027, long before any trial result. In October the company borrowed from K2 HealthVentures, repaid that loan in full and retired the old agreement.
The new facility matures in October 2030 and asks only for interest in the meantime. That interest-only period stretches further if X4 begins selling mavorixafor for the new use in America. Cash interest starts at 8.55%, under the 11.2% effective rate the company had been paying.
The switch was not free, because the payoff came to $78.7 million once end-of-term and termination fees were counted. But no principal falls due before the approval decision, which removes the harshest deadline a one-drug company can carry.
What to watch: whether the lenders release the second tranche. X4 may spend that money only on "permitted acquisitions and permitted investments", so a yes would buy options rather than launch costs.
XOLREMDI Sales Rose 77% on New Patients
XOLREMDI is the only product X4 sells, a pill for WHIM syndrome, a rare inherited disorder that leaves patients short of infection-fighting cells. The company cut marketing behind it last year to put its resources into the 4WARD trial.
Sales went up anyway. Net product revenue reached $2.8 million in the quarter, from $1.6 million a year earlier, and X4 credits an increase "in the number of patients who have been prescribed our drug product".
That matters because prescriptions now carry the revenue, and the same small commercial team would handle a far bigger launch later. Rebates, discounts and co-pay help took about 9% off gross sales, a light deduction for a rare-disease medicine.
What to watch: the fourth-quarter sales line and any patient count behind it. Steady additions would show the team can still win prescribers while the trial takes most of the attention and the money.
🐻 Bear Case
Cash Covers the Trial, Not the Launch
X4's results headline reads "Balance Sheet Provides Cash Runway into Q1 2029". The filing lodged the same week is narrower: the company says its money funds operations and debt payments "for at least the next 12 months", and adds that "we will need to raise additional capital, which cannot be assured".
The arithmetic leaves little room. That runway reaches early 2029 only while spending stays near this year's rate, and approval could arrive no sooner than the quarter the runway ends. Selling a drug costs more than testing one, because X4 would need a salesforce before the first prescription.
- Cash, equivalents and marketable securities: $187.7 million, from $253.0 million at the end of 2025
- Cash used by operations in nine months: $60.6 million
- Average quarterly burn, by our math: about $20 million
- Debt after the refinancing: $80 million, from $75 million
The new loan does not fill that gap, because X4 may draw the untapped tranche only for "permitted acquisitions and permitted investments". A covenant starting in October 2027 can also force the company to hold unrestricted cash worth three-quarters of what it owes, freezing much of the balance.
What to watch: the cash balance in the year-end report and the burn that comes with it. If spending holds near $20 million a quarter, X4 reaches its data with enough money to file an application and not enough to launch.
Share Count Quadrupled Over the Year
X4 pays for its trial by selling shares. Common shares outstanding reached 100.9 million at the end of September, against 25.1 million a year earlier, mostly through last autumn's offering.
The loss per share flatters the quarter. X4 reported 16 cents a share against 69 cents, while the loss itself narrowed by about a third. On last year's share count, this quarter's loss works out near 47 cents by our math.
More dilution is already arranged rather than hypothetical. An untouched $75 million programme lets the company sell stock into the market at will, and K2 may convert part of its loan into shares.
What to watch: whether the count climbs again in the fourth quarter without new cash arriving. Warrant exercises add shares and bring in almost nothing, because holders paid nearly the whole price when they bought.
Licence Revenue Fell Away This Year
Last year X4 sold the European rights to its pill to Norgine, a British company, for an upfront payment of €28.5 million plus milestones. Those payments, not prescriptions, produced most of the revenue the company reported in 2025.
What remains is thin. Licence and other revenue came to $0.1 million in the third quarter, because the European approval milestone landed in the spring and the marketing authorisation moved across to Norgine in July. Nine-month revenue dropped to $14.4 million from $32.5 million.
This matters because the reported revenue decline says nothing about demand. Remaining European milestones stay outside the accounts until X4 judges them probable, and royalties depend on how many packs its partner sells.
What to watch: the next milestone payment or the first royalty line from Norgine. Partner money costs X4 nothing in shares, so each payment that lands pushes back the next sale of stock.
Risks This Quarter Didn't Answer
X4 says little between quarters, and three standing questions got no figures this time. Each has an obvious place in the release or the filing, and in each case that place is empty.
- Participants already enrolled in 4WARD: not disclosed; the company repeats only that enrollment finishes this quarter.
- Patients taking XOLREMDI: not disclosed, so nobody can split the 77% sales rise between new patients and price.
- Result of handing the trial to an outside research firm, part of what X4 calls "a complete overhaul of the clinical operating infrastructure": no cost and no milestone given.
- Yearly dollar cost of the new loan: the rate and the fees appear in the filing, the cash figure does not.
What to watch: the enrollment confirmation promised for this quarter. A plain statement that 126 participants sit in the study settles the timing of the results; silence would push that doubt into 2028.
👓 Other Themes
4STEPS Trial Starts in Early 2027
X4 will run a second study, 4STEPS, in about 25 patients, with the first participant joining in the first quarter of 2027. Craig said it is "designed to evaluate how to safely reduce G-CSF dosage after starting mavorixafor while maintaining stable neutrophil counts". G-CSF is the injected drug patients use today. Results are due alongside 4WARD.
Market Research Lifts the Upper Patient Count
At its investor day the company presented research counting "approximately 15,000 U.S. patients mirroring the 4WARD trial population, with potential upside to approximately 30,000 patients", "subject to FDA labeling". A year ago X4 cited 15,000 patients, so the upper number is new. No prescription follows until the regulator agrees the wording of a label.
💲 Other KPIs
Pay in shares keeps climbing: $3.5 million in the quarter against $0.8 million a year ago. Almost all of it sits in administrative costs, which is why that line fell less than headcount did. Awards not yet charged reach $18.9 million, spread over 2.4 years.
Money owed to outside trial vendors but not yet paid fell to $2.6 million from $12.2 million at the end of December. Settling those bills drained cash: accrued expenses took $9.8 million out of operating cash over nine months. A thin balance leaves less cushion when trial invoices arrive together.
Drug stock rose to $5.5 million from $4.5 million at the end of 2025, with most of the increase in work in process. The build ties up cash now, yet it also prepares supply for a wider market, and finished goods actually came down over the same nine months.
🔮 Guidance
Extended. X4 now says its balance sheet funds the company into early 2029, a quarter beyond the statement it made a year ago. By our math that needs spending near $20.9 million a quarter, close to this year's rate, and the money runs out around the time approval could arrive. The filing itself commits only to the next twelve months.
Cut and later. X4 needs 50 fewer participants than the target it carried a year ago, and completion moved one quarter back. The regulator agreed the smaller study keeps adequate power on both main measures, which is why the reduction helps rather than hurts. Craig expects the last places filled by the end of December; the company has not said how many sit in the study today.
New in these materials. With enrollment closing this quarter and each participant followed for 52 weeks, results land in early 2028. Craig argues the pill is "uniquely positioned to transform the treatment landscape for patients with primary chronic neutropenia", and this is the readout that tests the claim.
Held, with a wider window. X4 still points to a decision around the end of 2028 but now allows for early 2029. The route runs through an application filed after the data, and the regulator has said the safety database "appears acceptable to support a potential sNDA", "although its adequacy would remain a review issue".
New. About 25 patients will test whether doctors can lower the dose of today's injected treatment once a patient starts the pill. Both readouts now sit in the same quarter of 2028, so X4 can file one package rather than two, and the extra study adds cost to a budget that already assumes flat spending.
❓ Key Questions
How many patients are already in the 4WARD study?
X4 says enrollment finishes this quarter but never gives a running count. Without one, nobody can judge whether the last places are nearly filled or whether the early-2028 data date carries real risk.
What will the new loan cost each year?
The filing gives a cash rate of at least 8.55% plus 1% paid in kind on $80 million, but no dollar figure. That interest comes straight out of a runway that assumes spending stays flat.
How many patients take XOLREMDI today?
Product sales rose 77%, which X4 puts down to more prescriptions. A patient number would show whether the base is a few dozen people or several hundred, and how repeatable the increase is.
What does the FDA say about the secondary measures?
X4 plans to send the agency more information on power for the key secondary endpoints. Those measures shape how broad a label the drug could win, and the company has not reported an answer.
Who will sell the drug in chronic neutropenia?
X4 licensed Europe to Norgine and cut its own commercial spending last year. It has not said whether it will build a US salesforce, find a partner, or what either route would cost.